Cargando…
Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals
AIMS: To identify, characterize and compare all Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals that included real‐world data on efficacy from expanded access (EA) programmes. METHODS: Cross‐sectional study of FDA (1955–2018) and EMA (1995–2018) regulatory approval d...
Autores principales: | Polak, Tobias B., van Rosmalen, Joost, Uyl – de Groot, Carin A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444779/ https://www.ncbi.nlm.nih.gov/pubmed/32200551 http://dx.doi.org/10.1111/bcp.14284 |
Ejemplares similares
-
Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals
por: Polak, Tobias B, et al.
Publicado: (2022) -
The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020) -
Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations
por: Polak, Tobias B., et al.
Publicado: (2022) -
Results from Expanded Access Programs: A Review of Academic Literature
por: Polak, Tobias B., et al.
Publicado: (2023) -
Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies
por: Constantinescu, Catalin, et al.
Publicado: (2020)